Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Contract development and manufacturing firm Almac Group is investing £16m to expand its formulation and analytical development services.
Subscribe to our email newsletter
The company completed negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, UK.
Almac will occupy the formulation development and analytical testing plants at the site.
A global pharma company designed and constructed the facilities as part of its formulation development, clinical manufacturing & analytical testing capabilities.
Almac has started recommissioning of the facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing.
The project is expected to create about 180 new jobs over the next five years and be operational in 2017.
Almac Pharma Services managing director Graeme McBurney: "As we experience increased client demand for our pharmaceutical development and niche commercial manufacturing services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and capability and further demonstrating our continued commitment to support our global clients in the development and manufacturing of their drug products."
Almac provides services to more than 600 worldwide companies within the pharmaceutical and biotech sectors.
The services include R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS technology through to commercial-scale manufacture.